Xenetic Biosciences (XBIO) AI Stock Analysis

• Market Cap: $3.76M
• Dividend Yield: N/A
• Average Volume (3M): 8.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.79
• Revenue Growth: -1.56%
• EPS Growth: 5.01%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 66
• Industry: Biotechnology
• EPS (TTM): -2.57
• Shares Outstanding: 1,542,139
• 10 Day Avg. Volume: 10,168
• 30 Day Avg. Volume: 8,184
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 2.08
• Price to Cash Flow (P/CF): -1.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

Xenetic Biosciences is currently facing substantial financial and operational challenges, as evidenced by its negative profitability and cash flow metrics. The technical analysis further supports a cautious outlook, with bearish indicators across key metrics. Valuation remains a concern due to the lack of earnings. However, the company's strong equity position and absence of debt offer some stability as it navigates these challenges.

Positive Factors

Clinical Development

Xenetic continued to make progress in advancing its DNase-based technology toward Phase 1 clinical development for pancreatic carcinoma and other locally advanced or metastatic solid tumors.

Strategic Partnerships

The agreement with PeriNess accelerates DNase I based oncology program clinical development by leveraging PeriNess's expertise in drug development from preclinical to early-stage clinical programs.

Therapeutic Advancement

Promising findings from completed studies reinforce confidence in the potential of Xenetic's approach, looking forward to the next steps as the company advances toward initiating Phase 1 studies.

Negative Factors

Clinical Trial Uncertainties

The research presented here underscores the role of NETs in modulating CAR-T cell efficacy as an adjunctive treatment.

Efficacy Concerns

These data suggest that DNase I administered in combination with CAR-T cells has the potential to bolster therapeutic responses in patients undergoing CAR-T cell therapy, particularly in solid tumors, an indication where CAR-T therapy efficacy has been limited.

Regulatory Challenges

The addition of the DNase-based platform has the potential for value-driving regulatory and clinical milestones for Xenetic.

Xenetic Biosciences Business Overview & Revenue Model

Company Description

Xenetic Biosciences, Inc. (XBIO) is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs. The company primarily operates in the field of oncology, leveraging its proprietary technologies to advance its drug development pipeline. Xenetic is known for its platform technologies that enhance the efficacy and safety profiles of biologic drugs, particularly in the treatment of cancer.

How the Company Makes Money

Xenetic Biosciences makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model primarily involves licensing its technologies to pharmaceutical partners, thereby earning milestone payments and royalties on the sales of drugs developed using its platforms. Xenetic also engages in collaborations and strategic partnerships to co-develop therapies, which may include upfront payments, research funding, and shared revenues from successful products. Additionally, the company may receive government grants and funding to support its research initiatives.

Xenetic Biosciences Financial Statement Overview

Summary

Overall, Xenetic Biosciences is grappling with profitability challenges, as reflected in its income statement and cash flow analysis. Despite a healthy equity position and no debt, the company must address its operational inefficiencies to improve profitability and cash flow generation. The financial stability from a strong balance sheet provides a foundation to support future growth initiatives.

Income Statement

Xenetic Biosciences has shown inconsistent revenue growth, with the latest annual revenue decreasing slightly by 1.6%. The gross profit margin remains strong at 100%, indicating efficient cost management relative to revenue. However, the company faces significant challenges with profitability, as evidenced by a negative net profit margin of -158.4% and consistent EBIT and EBITDA losses, reflecting operational inefficiencies.

Balance Sheet

The balance sheet shows a strong equity position with an equity ratio of 87%. The company has no debt, which minimizes financial risk and provides stability. However, the return on equity is negative due to ongoing net losses, highlighting challenges in generating shareholder returns.

Cash Flow

Operating cash flow remains negative, indicating ongoing cash consumption in operations. The free cash flow also reflects a negative trend, although there is a slight improvement from the previous year. The cash flow to net income ratios are not favorable due to negative net income, suggesting struggles in translating operational activities into positive cash flows.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.50M	2.54M	1.71M	1.16M	436.94K
	Gross Profit
2.50M	2.54M	1.68M	1.13M	436.94K
	EBIT
-4.20M	-4.52M	-6.72M	-5.75M	4.55M
	EBITDA
-4.20M	-4.54M	-6.72M	-5.71M	-4.69M
	Net Income Common Stockholders
-3.96M	-4.13M	-6.39M	-5.54M	-10.89M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.17M	8.98M	13.10M	18.24M	11.53M
	Total Assets
6.90M	10.61M	14.72M	19.82M	13.18M
	Total Debt
0.00	0.00	0.00	27.04K	62.52K
	Net Debt
-6.17M	-8.98M	-13.10M	-18.22M	-11.47M
	Total Liabilities
894.26K	809.59K	1.07M	1.42M	963.97K
	Stockholders Equity
6.01M	9.80M	13.65M	18.39M	12.22M
Cash Flow		Free Cash Flow
-2.82M	-4.11M	-5.15M	-4.74M	-4.27M
	Operating Cash Flow
-2.82M	-4.11M	-4.65M	-4.74M	-4.27M
	Investing Cash Flow
0.00	0.00	-500.00K	0.00	0.00
	Financing Cash Flow
0.00	0.00	0.00	11.45M	5.43M

Xenetic Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XBIO, the sentiment is Negative. The current price of 2.44 is below the 20-day moving average (MA) of 2.65, below the 50-day MA of 3.37, and below the 200-day MA of 3.85, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 34.17 is Neutral, neither overbought nor oversold. The STOCH value of 53.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XBIO.

Xenetic Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.19B	3.13	-40.94%	2.95%	17.94%	2.00%
XBIO	43 Neutral	$3.76M	―	-50.12%	―	-1.56%	5.01%
JAGX	42 Neutral	$3.71M	―	-522.60%	―	19.75%	95.65%
TOVX	41 Neutral	$3.77M	―	-87.31%	―	―	6.87%
KZIA	31 Underperform	$3.69M	―	-2639.52%	―	―	19.58%
OGEN	29 Underperform	$3.76M	―	-714.95%	―	-100.00%	76.55%

Xenetic Biosciences Corporate Events

Xenetic Biosciences Expands Collaboration for Cancer Treatment

Xenetic Biosciences has extended its collaboration with The Scripps Research Institute to further develop its DNase oncology platform. This initiative aims to enhance cancer treatment efficacy by targeting neutrophil extracellular traps, which promote cancer progression. The partnership focuses on combining DNase with CAR T-cell therapies, showing promise in preclinical studies for reducing tumor burden and improving therapeutic responses, with plans to advance towards clinical development for pancreatic and other solid tumors.